ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
10.12.2019 11:00:00 EET | Business Wire | Press release
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The round was co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. The financing will be used to complete the first-in-human trials with the company’s lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors. The funding will also be used to broaden the company’s novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.
“Recent advances in the understanding of the innate immune system’s role in cancer provide a unique opportunity for ImmunOs Therapeutics and our partners. We value the ongoing support of all the current investors and welcome all the Series A round participants, specifically Pfizer Ventures and BioMedPartners, both of whom have demonstrated a strong commitment to the oncology field,” said Sean R. Smith, CEO of ImmunOs Therapeutics AG.
Dr. Osiris Marroquin Belaunzaran, CSO and co-founder, added: “It is with great pleasure to see that our early research based on HLA open conformer modulation of immune cells is advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumor microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications."
In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include four new members: Dr. Markus Hosang of BioMedPartners; Dr. Michael Baran of Pfizer Inc.; Dr. Reinhard Ambros, former head Novartis Venture Fund; and Dr. Daniel Vasella, former Chairman and CEO Novartis.
Dr. Markus Hosang noted: “At BioMedPartners, we have over the last 15 years very successfully invested in and brought forward several innovative early-stage cancer companies. We got particularly attracted by ImmunOs and its novel approach that also adds to existing treatment modalities and thus has the potential to provide novel medicines to cancer patients who do not obtain a long-term benefit from current therapies.”
Dr. Michael Baran added: “Advances in understanding the role of the innate immune system is opening up opportunities to expand the potential of cancer immunotherapy. Pfizer Ventures is enthusiastic to support this emerging area through our investment in ImmunOs.”
About ImmunOs Therapeutics AG:
ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off company of the University of Zurich and the University of Basel, our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs proteins work directly on the innate immune system. (For more information, please visit www.immunostherapeutics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005042/en/
Contact information
Investor Relations
Wagistrasse 14
8952 Schlieren (Zurich Area), Switzerland
info@immunostherapeutics.com
International Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 or +49 30 23 63 27 68
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexGen Launches International Operations, Delivering Software and Services to Meet Demand for Battery Storage in Europe17.6.2026 15:00:00 EEST | Press release
FlexGen Power Systems, LLC. ("FlexGen"), a leading battery energy storage solution and energy management software provider, announced today that it continues to grow its global business by building its presence in Europe to increase battery storage capacity on local grids, supporting energy reliability and affordability. FlexGen offers its energy management system, including power plant controls (PPC), analytics, and site-level supervisory control and data acquisition (SCADA), as well as services, such as lifecycle services, integration abilities, and data centre leadership, to the European market to improve operational performance, increase availability, and unlock greater returns for battery storage developers and operators. “As Europe faces rising energy prices, high curtailment rates, and rising demand from electrification, FlexGen’s advanced software and services will meet local grid challenges and solve for energy independence, reliability, and affordability,” said Mike Wallace,
Moody’s Launches Decision-Grade AI Skills for Major AI Platforms17.6.2026 15:00:00 EEST | Press release
Moody’s Corporation (NYSE: MCO) today announced the release of its first set of AI skills – purpose-built, platform-agnostic instruction kits that encode Moody’s analytical frameworks and connect AI agents to its decision-grade intelligence. Available across compatible AI platforms beginning with Microsoft 365 Copilot Cowork, Moody’s skills enable customers to execute complex analytical workflows through a single natural-language request, with outputs grounded in Moody’s proprietary ratings, research, and risk intelligence. “Moody’s is among the first financial data providers to deliver a full library of skills on an open standard, and today’s launch is just the beginning,” said Cristina Pieretti, Head of Digital Content and Innovation at Moody’s. “AI platforms are becoming the interface for financial decision-making, and the next phase of adoption will be defined by execution. Skills are how we encode Moody’s expertise into that execution layer.” Skills are emerging as the standard fo
Rehlko and Liebherr Partner on Strategic Capacity Expansion to Support Accelerating Data Center Demand for Resilient Power Solutions17.6.2026 15:00:00 EEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, joined Liebherr Group (“Liebherr”) on June 2 for the strategic capacity expansion ceremony at the Liebherr-Components facility in Colmar, France. This event marks a key milestone in the continued expansion of Rehlko’s strategic partnership with Liebherr and a significant step in scaling resilient power solutions for the next generation of digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617213506/en/ Liebherr and Rehlko celebrate the strategic capacity expansion of Liebherr-Components Colmar factory. From left to right: Brian Melka (President and CEO of Rehlko), Jan Liebherr (President of the Administrative Board of Liebherr-International AG), Pietro Iemmi (CEO Liebherr-Component Technologies AG), and further members of Rehlko’s and Liebher
Thredd and Sutton Bank Partner to Power U.S. Card Program Expansion for Global Brands17.6.2026 15:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced a strategic partnership with Sutton Bank, a leading sponsor bank and card issuer for fintechs and embedded finance use cases. Through the partnership, Sutton Bank will serve as a BIN sponsor for Thredd clients seeking to launch and scale prepaid and debit card programs in the United States. The partnership strengthens the U.S. market proposition for global fintechs and embedded finance providers by providing these organizations access to an established U.S. issuing bank partner with a long-standing track record supporting card programs across the fintech ecosystem. Sutton Bank has become widely recognized for its payments business, including its work with card networks, processors and program managers, as well as its role as a large BIN sponsor for the fintech community. Together, Thredd and Sutton Bank will support companies looking to bring modern prepaid and debit card programs to market across the U.S. Thredd will pro
FEINDEF 27 Accelerates Commercialisation, Surpassing FEINDEF 25’s Total Exhibition Area by 25% With One Year to Go17.6.2026 14:41:00 EEST | Press release
One year ahead of FEINDEF 27, FEINDEF, Spain’s International Defence and Security Exhibition, continues to maintain a strong commercialisation pace, outperforming previous editions at the same stage. The exhibition has already surpassed the total exhibition area occupied at FEINDEF 25 by 25%, reflecting the strong interest across the sector in participating in the next edition and reinforcing its appeal amid the continued growth of the defence and security industry. Organised by the Fundación Feindef, the exhibition will hold its fifth edition from 18 to 20 May 2027 at IFEMA Madrid, with the objective of consolidating a new phase of growth and strengthening its position as a leading international platform bringing together institutions, industry stakeholders and professionals from across the defence and security ecosystem. In this context, FEINDEF 27 is expected to exceed 89,000 m² of total exhibition area, representing a 46% increase compared to FEINDEF 25 and expanding its capacity t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom